News | August 30, 2025
Lilly's Verzenio scores first OS improvement in breast Cancer
Treatment with Verzenio also resulted in sustained invasive disease-free survival and distant relapse-free survival benefit
Treatment with Verzenio also resulted in sustained invasive disease-free survival and distant relapse-free survival benefit
Data show adjuvant Verzenio plus endocrine therapy extends overall survival and sustains long-term improvements in invasive disease-free survival
2024 full-year revenue guidance raised by US$ 2 billion
Subscribe To Our Newsletter & Stay Updated
